Biocartis Group Valuation
Is BCART undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BCART?
Other financial metrics that can be useful for relative valuation.
|What is BCART's n/a Ratio?|
Price to Sales Ratio vs Peers
How does BCART's PS Ratio compare to its peers?
|BCART PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
IBAB Ion Beam Applications
7792 Colan Totte.Co.Ltd
BCART Biocartis Group
Price-To-Sales vs Peers: BCART is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (15.3x).
Price to Earnings Ratio vs Industry
How does BCART's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Sales vs Industry: BCART is good value based on its Price-To-Sales Ratio (1x) compared to the European Medical Equipment industry average (4.9x)
Price to Sales Ratio vs Fair Ratio
What is BCART's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1x|
|Fair PS Ratio||0.7x|
Price-To-Sales vs Fair Ratio: BCART is expensive based on its Price-To-Sales Ratio (1x) compared to the estimated Fair Price-To-Sales Ratio (0.7x).
Share Price vs Fair Value
What is the Fair Price of BCART when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BCART's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BCART's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
- Take a look at our analysis of BCART's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Biocartis Group regulatory filings.